The company said revenue for Q1 2025 was $4.8 billion, up 3% year over year as reported and 4% on an Organic basis. Net income margin was 11.8% versus 8.0% a year earlier, and diluted earnings per share were $1.23 versus $0.81.

1. 01

   The company said revenue for Q1 2025 was $4.8 billion, up 3% year over year as reported and 4% on an Organic basis. Net income margin was 11.8% versus 8.0% a year earlier, and diluted earnings per share were $1.23 versus $0.81.

2. 02

   GE HealthCare said cash flow from operating activities for Q1 2025 was $250 million, down $169 million from $419 million a year earlier. Free cash flow (non-GAAP) was $98 million, down $175 million from $274 million a year earlier.

3. 03

   The company said it updated its full-year 2025 outlook to include the estimated impact of expected tariffs. Adjusted EBIT margin is now 14.2% to 14.4% (previously 16.7% to 16.8%), adjusted EPS is $3.90 to $4.10 (previously $4.61 to $4.75), and free cash flow is at least $1.2 billion (previously at least $1.75 billion).

4. 04

   The company said its Board of Directors authorized a common stock repurchase program of up to $1.0 billion on April 30, 2025. The program has no expiration date. The company said the timing and amount of repurchases are at its discretion and that it is not obligated to repurchase a specific amount.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.